SCHEDULE: Invus Group Increases Stake in enGene Therapeutics to 9.3%

Investment group Invus discloses an increased beneficial ownership of enGene Therapeutics' common shares, now holding 9.3% of the outstanding stock.

Summary

• Invus Public Equities, L.P. and its affiliated entities, collectively referred to as the Reporting Persons, have updated their beneficial ownership filing for enGene Therapeutics Inc.
• As of June 30, 2026, the Reporting Persons collectively beneficially own 6,256,662 common shares of enGene Therapeutics Inc.
• This represents 9.3% of the total outstanding common shares.
• The filing details the ownership structure, with Invus Public Equities holding 5,481,984 shares and Avicenna Life Sci Master Fund LP holding 774,678 shares.
• Raymond Debbane, as the managing member of key entities, is identified as having control over the aggregate beneficial ownership.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not unexpected increase in beneficial ownership by a known investment group.

Positives

• Significant investment stake by a known investment group, indicating confidence in the company's prospects.
• Clear disclosure of ownership, providing transparency to the market.
• The total beneficial ownership of 9.3% is a substantial holding.

Negatives

• The filing does not contain new operational or financial performance data, only ownership changes.
• The increase in ownership, while significant, is not presented with specific strategic intentions beyond general investment.

Risks

• Potential for further changes in ownership by the Reporting Persons, which could impact share price volatility.
• Concentration of ownership among a few entities could influence corporate governance decisions.

Future Outlook

This filing is primarily an ownership disclosure and does not contain forward-looking statements or specific future guidance from the company.

Management Comments

• Raymond Debbane certifies that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that increased institutional ownership, as reported in this Schedule 13G, is a common occurrence in the biotechnology sector, often reflecting investor sentiment towards companies in clinical development or with emerging therapeutic platforms.

Stakeholder Impact

• Shareholders: Increased institutional ownership may signal increased stability or potential for future strategic involvement.
• Management: May face increased scrutiny or influence from a significant shareholder group.
• Potential Investors: The disclosure provides transparency on a major shareholder's position.

Next Steps

• Continued monitoring of Invus Group's ownership and potential future filings.
• Observation of enGene Therapeutics' strategic and operational developments.

Key Dates

Keywords

enGene Therapeutics, Schedule 13G, beneficial ownership, Invus Group, Raymond Debbane, investment stake, common shares